Clinical Trial

Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD). The main question\[s\] it aims to answer are: \[question 1\] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? \[question 2\] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-02; most recent amendment 2025-02-10.
Trial Details
NCT Number NCT05974904
Lead Sponsor Chongqing Medical University
Conditions Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
Enrollment 7,000 participants
Start Date 2023-07-18
Primary Completion 2026-12-28 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2025-02-12